| Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME) (NCT01997164) | Regeneron Pharmaceuticals | 2014-11-01 |
| NVAMD Satellite Study (NCT02251366) | Johns Hopkins University | 2014-10-01 |
| Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration (NCT03744767) | Dr Irmela MANTEL | 2014-09-19 |
| Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (NCT02161575) | Novartis Pharmaceuticals | 2014-08-28 |
| An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration (NCT02591914) | Retinal Consultants of Arizona | 2014-02-01 |
| Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. (NCT02321839) | Nagoya City University | 2014-01-01 |
| Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. (NCT01942213) | Prism Vision Group | 2013-12-01 |
| Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD (NCT02810808) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2013-12-01 |
| Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (NCT01958918) | Novartis Pharmaceuticals | 2013-10-23 |
| Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. (NCT01918878) | Hadassah Medical Organization | 2013-10-01 |
| Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration (NCT01926977) | Arshad Khanani | 2013-09-01 |
| Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab (NCT02309281) | Vista Klinik | 2013-05-01 |
| Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) (NCT01863199) | Retinal Consultants of Arizona | 2013-05-01 |
| Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (NCT01775124) | Novartis Pharmaceuticals | 2013-02-22 |
| Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD). (NCT01624636) | Novartis Pharmaceuticals | 2012-12-01 |
| Neovascular Age-related Macular Degeneration (NCT01712035) | Oregon Health and Science University | 2012-10-01 |
| Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion (NCT01291121) | Yonsei University | 2011-02-01 |
| Safety and Tolerability Study for Age-Related Macular Degeneration (NCT01485588) | Iconic Therapeutics, Inc. | 2010-12-01 |
| A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD (NCT01157715) | Chengdu Kanghong Biotech Co., Ltd. | 2010-05-01 |
| Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD) (NCT00964795) | Regeneron Pharmaceuticals | 2009-12-01 |
| Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration (NCT01027468) | Medical University of Vienna | 2009-08-01 |
| A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD (NCT01242254) | Chengdu Kanghong Biotech Co., Ltd. | 2009-08-01 |
| Supplemental Adjuvants for Intracellular Nutrition and Treatment (NCT00893724) | Mid-Atlantic Retina Consultations, Inc. | 2009-06-01 |
| ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration (NCT00709527) | Ophthotech Corporation | 2008-10-16 |
| Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration (NCT00767949) | Lpath, Inc. | 2008-10-01 |
| Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration (NCT00764738) | Retina Macula Institute | 2008-10-01 |
| Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. (NCT00858208) | Pfizer | 2008-03-01 |
| The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study (NCT00599222) | Anders Kvanta | 2008-02-01 |
| Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration. (NCT00820742) | Pfizer | 2008-02-01 |
| Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD (NCT00574093) | Fondazione G.B. Bietti, IRCCS | 2008-01-01 |
| A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. (NCT00549055) | Pfizer | 2007-11-01 |
| The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) (NCT00640640) | Sheba Medical Center | 2007-08-01 |
| Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration (NCT00696592) | University of Padova | 2007-01-31 |
| Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD (NCT00383370) | Regeneron Pharmaceuticals | 2006-10-01 |
| Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD (NCT00370539) | Shahid Beheshti University of Medical Sciences | 2006-09-01 |
| Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration (NCT00967213) | Novartis Korea Ltd. | 2006-08-01 |
| Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD (NCT00370370) | Shahid Beheshti University of Medical Sciences | 2005-11-01 |
| An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD (NCT00373659) | University of Miami | 2004-08-01 |
| Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study) (NCT00344227) | University of Miami | 2004-08-01 |
| Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone (NCT00685100) | Medical University of Vienna | 2004-01-01 |
| Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration (NCT02450981) | Biocad | |